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Objective. To explore the feasibility of DNA methylation analysis for the detection of cervical neoplasia in
self-obtained cervico-vaginal lavages.
Methods. Lavages collected by a self-sampling device and paired cervical scrapings were obtained from 20
cervical cancer patients and 23 patients referred with an abnormal cervical smear (15 with high-grade
cervical intraepithelial neoplasia (CIN2+) and 8 without CIN). All lavages and scrapings were analyzed by
liquid based cytology (LBC), Hybrid Capture II (HC-II) for hr-HPV DNA detection and by DNA methylation
analysis (JAM3, TERT, EPB41L3 and C13ORF18). Concordance between lavages and scrapings was measured by
Cohen's Kappa (k).
Results. In lavages and scrapings from cervical cancer patients (n=20), methylation analysis was positive
in 19 (95%) and 19 (95%), HC-II in 16 (80%) and 15 (75%) and LBC in 15 (75%) and 19 (95%), respectively. In
lavages and scrapings from CIN2+ patients (n=15), methylation analysis was positive in 10 (67%) and 12
(80%), HC-II in 15 (100%) and 15 (100%) and LBC in 11 (73%) and 12 (80%), respectively. Concordance
between cervical scrapings and lavages (n=43) was for LBC k=0.522 (pb0.001), hr-HPV testing k=0.551
(pb0.001) and DNA methylation analysis k=0.653 (pb0.001).
Conclusions. DNA methylation analysis in cervico-vaginal lavages obtained by a self-sampling device is
feasible and its diagnostic performance appears to be at least comparable to the detection of cervical
neoplasia by cytomorphology and hr-HPV. Our pilot study suggests that detection of cervical neoplasia by
DNA methylation analysis in cervico-vaginal lavages warrants exploration of its use in large prospective
studies.
© 2010 Elsevier Inc.Open access under the Elsevier OA license.Introduction
Current population-based screening programs for detection of
(pre)malignant cervical lesions are based on cytomorphological
assessment of cervical scrapings. Cytological screening is not an
ideal method with sensitivity for CIN2+ of 55% [1]. Cervicalce B.V., Scherpenzeel, The
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evier OA license.carcinogenesis is highly associated with high-risk human papilloma-
virus (hr-HPV) infection and hr-HPV is detected in almost all high-
grade cervical intraepithelial neoplasia (CIN2+) and cervical cancers
[2,3]. Hr-HPV testing of cervical scrapings has been shown to improve
sensitivity of cervical screening [4]. However, one of the major
problems of hr-HPV testing is the low speciﬁcity, especially for young
women [5], resulting in a high false-positive rate.
DNA promoter methylation of tumor suppressor genes has been
reported to be an early event in cervical carcinogenesis [6].
Therefore, a test based on methylation markers could be relevant
for the early detection of cervical neoplasia especially using markers
that are not methylated in normal cells. Various methylated gene
promoters have been identiﬁed, although none of these markers
have a sufﬁciently high sensitivity and/or speciﬁcity to be used as
primary screening tool in population-based screening [7]. Recently,
in our search for cervical cancer speciﬁc methylation markers with a
speciﬁcity of ~100% and the highest sensitivity (N80%) [8], we
identiﬁed 4 markers (JAM3, TERT, EPB41L3 and C13ORF18) out of
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literature in combination fulﬁlling these criteria [9,10]. Since, in our
laboratory, these 4 markers currently form the most optimal
methylation marker panel available, we used this 4-gene panel in
the present study.
Apart from improving screening tests technically, a major problem
in current population-based screening programs for cervical neoplasia
is the participation rate. In the Netherlands, the total non-responders
group is around 30%, which is comparable to other countries with
population-based screening programs. Unfortunately, half of the
cervical cancers are diagnosed in this group of women [11–15].
Introduction of a self-sampling method resulted in an increase of the
participation rate of a non-responder group up to 30% [16,17]. In
countries currently without a population-based screening program
for cervical neoplasia, self-sampling might be also a practical
alternative.
A recent study showed that hr-HPV testing in self-obtained lavages
is representative for detection of current HPV infections, while in
contrast cytomorphological assessment, liquid based cytology (LBC),
of these lavages appeared to be not representative for the underlying
cervical neoplasia [18]. Until now, no data on DNA methylation
analysis in cervico-vaginal lavages are available.
The aim of the present pilot study was to explore the feasibility of
DNA methylation analysis for detection of cervical neoplasia in self-
obtained cervico-vaginal lavages. In that respect we compared 1)
results from DNA methylation analysis in cervico-vaginal lavages
obtained by a self-sampling device to DNA methylation analysis on
cervical scrapings collected from the same patients and 2) the
detection of CIN2+ by DNA methylation analysis to a currently
available methodology such as HC-II and LBC.Patients and methods
Patients
Patients referred for cervical cancer or with an abnormal cervical
smear were asked to participate in this study during their initial visit
to the outpatient clinic of the University Medical Center Groningen.
For all cervical cancer patients, an examination under general
anesthesia was planned for staging in accordance with the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) criteria. During
this examination, samples were taken by a gynecologist. For patients
referred with an abnormal cervical smear, samples were taken during
routine gynecologic examination at the ﬁrst outpatient clinic visit. In
all patients, cervico-vaginal cells were collected ﬁrst with a self-
sampling device (Delphi Screener®, Delphi Bioscience B.V., Scher-
penzeel, The Netherlands), followed by a cervical scraping. Twenty
consecutive cervical cancer patients (in the period of November
2007–March 2008) were included in this study and twenty-three
consecutive patients referred with an abnormal cervical smear
(October 2008–May 2009). Histological classiﬁcation of cervical
cancer patients revealed 15 with squamous cell carcinoma (75%), 4
with adenocarcinoma (20%) and 1 with adenosquamous carcinoma
(5%). These patients were divided into 9 (45%) FIGO stage IB1, 3 (15%)
FIGO stage IB2, 1 (5%) FIGO stage IIA, 4 (20%) FIGO stage IIB, 1 (5%)
FIGO stage IIIA and 2 (10%) FIGO stage IIIB. The median age of the
cervical cancer patients was 45 years (range 22–85 years). Histolog-
ical classiﬁcation of patients referred with an abnormal cervical smear
revealed 3 micro-invasive carcinoma, 8 CIN3, 4 CIN2 (15=CIN2+)
and 1 CIN1 and 7 no dysplasia (CIN0) (8=CIN0/1). Median age of
patients referred with an abnormal cervical smear was 35 years
(range 22–61 years). This study was approved and followed the
ethical guidelines of the Institutional Review Board of the University
Medical Center Groningen. All patients gave written informed
consent.Sample collection and DNA extraction
Cervico-vaginal cells were collected using a self-sampling device
as described previously [18]. In brief, the instrument is ﬁlled with 5 ml
buffered saline and after release of the buffered saline into the vagina,
the buffered saline is aspirated back automatically by releasing the
plunger. The solution containing cervico-vaginal cells was collected in
ethanol–carbowax (2% polyethylene glycol, 50% ethanol). A total
volume of 10 ml containing cervico-vaginal cells was divided into 3
fractions for cytomorphological assessment (2 ml), Hybrid Capture II
HPV testing (2 ml) and DNA isolation (6 ml). The cervical scrapings
were collected using the Cervex-Brush® Combi Sterile (Rovers
Medical Devices B.V., Oss, The Netherlands) and cells were resus-
pended in 5 ml PBS. Threemilliliters was stored for DNA isolation. One
milliliter was resuspended in one milliliter carbowax for cytomor-
phology and one milliliter in one milliliter carbowax for Hybrid
Capture II HPV testing. Samples for Hybrid Capture II HPV testingwere
stored at 4 °C and samples for DNA isolation were stored at −80 °C.
LBCwas performed on cytospins (from lavages and cervical scrapings)
that were Pap-stained and routinely classiﬁed by two cytologists and a
pathologist without knowledge of the molecular and clinical data.
DNA isolation was performed using standard salt–chloroform extrac-
tion and isopropanol precipitation. Precipitated DNA was resus-
pended in 150 μl of Tris–EDTA buffer. Genomic DNAwas ampliﬁed in a
multiplex PCR according to the BIOMED-2 protocol, to check the DNA
quality [19].Quantitative methylation speciﬁc PCR (QMSP)
QMSP was performed as we described previously [9,20]. In short,
bisulﬁte treatment on denatured genomic DNA was performed with
the EZ DNA methylation kit according to manufacturer's protocol
(Zymogen, BaseClear, Leiden, The Netherlands). To correct for total
DNA input, QMSP of the housekeeping gene β-actin was used as a
reference. QMSP was carried out in a total volume of 20 μl in 384 well
plates in an Applied Biosystems 7900HT Fast Real-Time PCR System
(Applied Biosystems, Nieuwekerk a/d IJsel, The Netherlands). The
ﬁnal reaction mixture consisted of 600 nM of each primer, 200 nM
probe, 1× QuantiTect Probe PCR Kit (Qiagen, Venlo, The Netherlands)
and 50 ng of bisulﬁte converted genomic DNA. As a positive control,
serial dilutions of genomic leukocyte DNA, in vitro methylated with
SssI (CpG) methyltransferase (New England Biolabs. Inc., Beverly,
MA), were used in each experiment. DNA methylation analysis was
performed for four genes (JAM3, TERT, EPB41L3 and C13ORF18) in
triplicate. The QMSP primer and probe sequences used in this study
are given in Table 1. DNA methylation analysis was scored positive
when one of the genes showed any DNA methylation.HPV detection
For detection of the presence of hr-HPV, standard Digene Hybrid
Capture II (HC-II) DNA testing was used according to manufacturer's
protocol (http://www.qiagen.com).Statistical analysis
To determine the detection rate, CIN2+ was taken as a cut off
value for the three tests in cervical scrapings and lavages. Concor-
dance between cervical scrapings and lavages was measured by
Cohen's Kappa. In cervical cancer patients, visible tumor cells in both
samples were taken as cut off value to measure concordance for LBC.
In patients referred with an abnormal cervical smear, moderate
dysplasia was taken as cut off value to measure concordance for LBC.
Statistical signiﬁcance was assumed if the p value was b0.05.
Table 1
Sequences DNA methylation markers.
Marker Forward primer Reverse primer Probe
C13ORF18 TTTTTAGGGAAGTAAAGCGTCG ACGTAATACTAAACCCGAACGC AGATGGAAGAAATTTTGGAGATGCGCGTT
JAM3 GGGATTATAAGTCGCGTCGC CGAACGCAAAACCGAAATCG TAACCGCCTCAACGCCATATCGAAAATTACTAA
EPB41L3 GGGATAGTGGGGTTGACGC ATAAAAATCCCGACGAACGA AAATTCGAAAAACCGCGCGACGCCGAAACCA
TERT GGTTTCGATAGCGTAGTTGTTTC CTACACCCTAAAAACGCGAAC AAAAAACGCGACCCAAACCCCCGAAT
ACTIN TGGTGATGGAGGAGGTTTAGTAAGT AACCAATAAAACCTACTCCTCCCTTAA ACCACCACCCAACACACAATAACAAACACA
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In this study, 20 patients referred with cervical cancer and 23
patients with an abnormal cervical smear were included. DNA
methylation analysis was positive in 95% (19/20) of cervical cancer
scrapings and in 95% (19/20) cervical cancer lavages, with both
negative cases shown in two different patients. DNA methylation
negative cervical cancer scraping and lavage both contained tumor
cells, according to LBC. DNA methylation analysis was positive in 80%
(12/15) CIN2+ cervical scrapings and 67% (10/15) CIN2+ lavages.
DNA methylation analysis was positive in 0% (0/8) CIN0/1 cervical
scrapings and 25% (2/8) CIN0/1 lavages. Concordance between
cervical scrapings and lavages (n=43) for the methylation test was
k=0.653 (pb0.001). Detailed information about the 4 different
methylation markers used in our methylation marker panel is given
in Table 2.
Hr-HPV was detected by HC-II in 75% (15/20) cervical cancer
scrapings and in 80% (16/20) of cervical cancer lavages. In CIN2+
patients, hr-HPV was detected in 100% (15/15) of cervical scrapings
and 100% (15/15) of lavages. Hr-HPV was detected in 63% (5/8) CIN0/
1 cervical scrapings and 88% (7/8) CIN0/1 lavages. Concordance
between cervical scrapings and lavages (n=43) for hr-HPV detection
by HC-II was k=0.551 (pb0.001).Table 2
LBC, HC-II and DNA methylation analysis results for cervical scrapings and cervico-
vaginal lavages.
Test Detection rate
CxCa (n=20)
Cervical scraping
Detection rate
CxCa (n=20)
Lavage
LBC 95% (19/20) 75% (15/20)
HC-II 75% (15/20) 80% (16/20)
C13ORF18 55% (11/20) 50% (10/20)
JAM3 75% (15/20) 90% (18/20)
EPB41L3 90% (18/20) 75% (15/20)
TERT 80% (16/20) 85% (17/20)
METH analysis 95% (19/20) 95% (19/20)
Test Detection rate
CIN2+ (n=15)
Cervical scraping
Detection rate
CIN2+ (n=15)
Lavage
LBC 80% (12/15) 73% (11/15)
HC-II 100% (15/15) 100% (15/15)
C13ORF18 27% (4/15) 20% (3/15)
JAM3 67% (10/15) 60% (9/15)
EPB41L3 73% (11/15) 60% (9/15)
TERT 40% (6/15) 47% (7/15)
METH analysis 80% (12/15) 67% (10/15)
Test Detection rate
CIN0/1 (n=8)
Cervical scraping
Detection rate
CIN0/1 (n=8)
Lavage
LBC 13% (1/8) 13% (1/8)
HC-II 63% (5/8) 88% (7/8)
C13ORF18 0% (0/8) 0% (0/8)
JAM3 0% (0/8) 13% (1/8)
EPB41L3 0% (0/8) 13% (1/8)
TERT 0% (0/8) 0% (0/8)
METH analysis 0% (0/8) 25% (2/8)LBC revealed tumor cells in 95% (19/20) cervical cancer scrapings
and in 75% (15/20) cervical cancer lavages. LBC revealed moderate
dysplasia or worse in 80% (12/15) cervical scrapings from CIN2+
patients and in 73% (11/15) lavages. LBC revealed no or mild dysplasia
in 7/8 cervical scrapings from CIN0/1 patients and in 7/8 lavages.
Concordance between cervical scrapings and lavages (n=43) for LBC
was k=0.522 (pb0.001).
Discussion
Our study shows for the ﬁrst time that detection of DNA
methylation in cervico-vaginal lavages obtained by a self-sampling
device is feasible and appears to be comparable with the methylation
status in cervical scrapings obtained from the same patient. Detection
of cervical cancer and CIN2+ patients in lavages by the methylation
test was high and concordant with cervical scrapings.
Although the number of cervical cancer patients in this pilot study
is relatively small, our data point to a potentially high detection rate
(N95%) of cervical cancer patients by DNAmethylation analysis of our
4 markers in cervico-vaginal lavages. Our QMSP assays apparently
need only a few neoplastic cells or breakdown DNA from neoplastic
cells to detect gene promoter methylation and this might explain our
observation that 5 cervical cancer lavageswere tested positive by DNA
methylation analysis, while by LBC, no tumor cells were observed. In
general, cervico-vaginal lavages contain many normal vaginal cells
and therefore a relatively few abnormal cells can easily be missed by
cytomorphological assessment of these lavages. Therefore, QMSP
assays seem to be more robust than cytomorphological assessment. In
2 cervico-vaginal lavages from the CIN0/1 patients, methylation was
detected. Because patients in this CIN0/1 group were referred to our
out clinic hospital with an abnormal Pap smear, a higher rate of
methylation might be expected as was also seen for hr-HPV. To
determine the exact speciﬁcity and false-positive rate of the
methylation test in cervico-vaginal lavages, DNAmethylation analysis
should be further tested in a large cervico-vaginal lavage control
group without an abnormal Pap smear and normal histology.
Cervico-vaginal lavages have previously been shown to be
representative for detection of current hr-HPV DNA [18]. In the
future, population-based screening programs for cervical neoplasia
might be based on hr-HPV testing, a very sensitive test, in
combination with a triage test, such as DNA methylation analysis
[9]. Such a combination test should have a high sensitivity in
combination with a high positive predictive value, the latter
preventing massive referrals to gynecologists for further examination.
An additional important advantage of DNA methylation analysis as a
triage test after hr-HPV testing is that both tests can be performed on
the same sample, thereby avoiding additional gynecologic examina-
tion of the patients. The value of combining hr-HPV testing with DNA
methylation analysis in a self-sampling approach needs to be further
explored.
LBC is a test with a very high speciﬁcity and has been suggested
also to be used as a triage test. However, as is shown in our pilot study,
5 of 20 cervical cancer patients were missed by LBC in cervical cancer
lavages compared to 1 of 20 in cervical cancer scrapings. It therefore
seems that LBC after hr-HPV testing is less effective in patients known
to have cervical cancer in a lavage compared to visual scraping.
283J.J.H. Eijsink et al. / Gynecologic Oncology 120 (2011) 280–283In conclusion DNA methylation analysis in cervico-vaginal lavages
obtained by a self-sampling device is feasible and its diagnostic
performance appears to be at least comparable to the detection of
cervical neoplasia by cytomorphology and hr-HPV. Our pilot study
suggests that detection of cervical neoplasia by DNA methylation
analysis in cervico-vaginal lavages warrants exploration of its use in
large prospective studies.
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